Volume Buzz: Cincinnati Bell Inc, General Electric Company, Gilead Sciences, Boston Scientific Corporation

NEW YORK, March 04, 2013 - vb-news.net, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on Cincinnati Bell Inc, General Electric Company, Gilead Sciences, Boston Scientific Corporation.Last week, Cincinnati Bell Inc.(NYSE:CBB), provider of telecomm services, in the fourth quarter of the year 2012, they have an adjusted loss of one cent per share thereby missing the Zacks Consensus Estimate’s earning of 4 cents per share. The results have also slumped from the previous year’s earnings of 3 cents. Is CBB a Buy After The Recent Slump? Let’s Find Out Here http://vbtrendreport.com/aw/?code=CBBThe adjusted earnings per share reached 11 cents in the year 2012, which was deterioration from the previous year’s 24 cents. There was an increase in revenue of 3% over the year which amounted to 374.7 million which beat the revenue of Zacks Consensus Estimate of 368 million. Last week, the stock slumped over 30%.In other news, the finance department of General Electric Company(NYSE:GE) is in the final stage of a regulatory review to assess if it requires extra scrutiny because of the outcome that its potential failure would trigger to the US economy.GE based in Connecticut, Fairfield said in a filing that GE Capital is kept under consideration for a proposed determination as a non-bank systematically significant financial institution. A determination as such would subject GE Capital to proposed improved supervisory standards. The filing confirms a report in October that GE Capital was kept under consideration to be thought as systematically crucial. Prudential Financial and American International Group are among the other insurers that are in the final stage of review. Is GE On The Way To Move Back To New highs? Get Free Report Here http://vbtrendreport.com/aw/?code=GEA trial drug combination from Medivir AB and Gilead Sciences, Inc.(NASDAQ:GILD) has eliminated the virus that was root of Hepatitis C in people suffering from liver disease. The trial included 90 patients, who had tried other medicines and did not respond. They all took a two0drug combination of Sofosbuvir of Gilead and Simeprevir of Medivir for a span of 12-24 weeks, along with and without ribavirin. The study was elaborated at a Conference on Retroviruses and Opportunistic Infection.Is GILD a Buy At New highs? Get Free research report On Pharma Industry Here http://vbtrendreport.com/aw/?code=GILDBoth Medivir and Gilead are in competition with Vertex Pharmaceuticals, Merck & Co and Bristol Myers Squibb in their venture to make a new generation of treatment medications for hepatitis C that eliminates the need to undergo standard therapy of ribavirin with interferon. The latter is an injected immune-boosting protein that can result in side effects like flu for as much as 48 weeks. Among 10 people, who had been taken off their treatments for a span of 12 weeks, the virus remained suppressed in all of them. In other news, Boston Scientific Corporation(NYSE:BSX) has stated on Thursday that its subsidiary, Boston Scientific Japan has agreed with Fukuda Denshi, a Japanese company, to promote and distribute Spinal Cord Precision Plus System of Boston Scientific in Japan.Get Latest News, Rumours on BSX Here http://vbtrendreport.com/aw/?code=BSXThe product is a part of neuromodulation division of Boston Scientific, which happens to be a fast-evolving business of the company in terms of sales. Japan stands as the second largest medical device market in the world. As per the release, Fukuda Denshi already flaunts extensive sales resources and a distribution infrastructure in Japan that can help in marketing the product.Over 60,000 patients are already using the Precision Plus System, as revealed by Boston Scientific. Fukuda Denshi is slated to start distributing the product from 1st April of 2013. About vb-news.netvb-news.net’s team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.DisclaimerThe assembled information disseminated by vb-news.net is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. vb-news.net does expect that investors will buy and sell securities based on information assembled and presented in vb-news.net. PLEASE always do your own due diligence, and consult your financial advisor.Contacts:vb-news.net 1419 Westwood Blvd Los Angeles, CA90024-4911staff@vb-news.netwww.vb-news.net

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here